Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ABEONASDAQ:ALDXNASDAQ:KALANASDAQ:MBIONASDAQ:TLC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABEOAbeona Therapeutics$3.41-53.7%$7.49$2.83▼$9.01$93.26M1.49400,321 shs5.50 million shsALDXAldeyra Therapeutics$3.91-0.5%$3.61$1.42▼$11.97$231.46M1.51585,790 shs452,218 shsKALAKALA BIO$6.50+2.7%$7.41$5.10▼$19.35$18.33M-1.8526,031 shs5,284 shsMBIOMustang Bio$0.36+5.9%$0.98$0.33▼$8.17$3.74M1.59178,352 shs126,086 shsTLCTaiwan Liposome$7.00$7.10$4.07▼$7.70$294.54M0.99133,095 shs12,421 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABEOAbeona Therapeutics-53.67%-56.06%-55.19%-28.36%+0.59%ALDXAldeyra Therapeutics-0.51%+1.03%+34.83%+30.33%-58.62%KALAKALA BIO+2.69%-5.66%-18.65%-9.34%-58.73%MBIOMustang Bio+5.79%-1.72%-66.69%-73.74%-91.46%TLCTaiwan Liposome0.00%0.00%0.00%0.00%0.00%The A.I. story nobody is telling you (Read ASAP) (Ad)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABEOAbeona Therapeutics3.5879 of 5 stars3.51.00.04.51.61.70.6ALDXAldeyra Therapeutics2.2257 of 5 stars3.53.00.00.02.52.50.0KALAKALA BIO3.6232 of 5 stars3.55.00.04.40.00.80.0MBIOMustang Bio2.0228 of 5 stars3.55.00.00.02.40.00.0TLCTaiwan LiposomeN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABEOAbeona Therapeutics3.00Buy$36.00955.72% UpsideALDXAldeyra Therapeutics3.00Buy$9.33138.70% UpsideKALAKALA BIO3.00Buy$18.00176.92% UpsideMBIOMustang Bio3.00Buy$17.254,695.66% UpsideTLCTaiwan LiposomeN/AN/AN/AN/ACurrent Analyst RatingsLatest ABEO, TLC, ALDX, KALA, and MBIO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024ABEOAbeona TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$36.004/3/2024ALDXAldeyra TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeMarket Perform ➝ Outperform$10.004/2/2024ALDXAldeyra TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/2/2024KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$22.00 ➝ $21.004/1/2024KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$15.00(Data available from 4/24/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABEOAbeona Therapeutics$3.50M26.65N/AN/A$0.60 per share5.68ALDXAldeyra TherapeuticsN/AN/AN/AN/A$2.04 per shareN/AKALAKALA BIO$3.89M4.71N/AN/A$2.79 per share2.33MBIOMustang BioN/AN/AN/AN/A$0.01 per shareN/ATLCTaiwan Liposome$3.63M81.14N/AN/A$0.83 per share8.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABEOAbeona Therapeutics-$54.19M-$2.58N/AN/AN/AN/A-280.58%-76.90%5/9/2024 (Estimated)ALDXAldeyra Therapeutics-$37.54M-$0.64N/AN/AN/AN/A-29.45%-24.24%5/2/2024 (Estimated)KALAKALA BIO-$42.20M-$17.94N/AN/AN/AN/A-281.02%-65.57%5/14/2024 (Estimated)MBIOMustang Bio-$51.60M-$6.00N/A∞N/AN/A-433.08%-146.39%5/10/2024 (Estimated)TLCTaiwan Liposome-$35.02M-$0.88N/AN/AN/A-299.27%-120.45%-55.11%N/ALatest ABEO, TLC, ALDX, KALA, and MBIO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024Q4 2023KALAKALA BION/A-$3.18-$3.18-$3.18N/AN/A3/18/2024Q4 2023ABEOAbeona Therapeutics-$0.51-$0.64-$0.13-$0.64N/AN/A3/11/2024Q4 2023MBIOMustang Bio-$1.68-$0.71+$0.97-$0.71N/AN/A3/7/2024Q4 2023ALDXAldeyra Therapeutics-$0.21-$0.08+$0.13-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABEOAbeona TherapeuticsN/AN/AN/AN/AN/AALDXAldeyra TherapeuticsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/ATLCTaiwan LiposomeN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABEOAbeona TherapeuticsN/A4.154.15ALDXAldeyra TherapeuticsN/A6.646.64KALAKALA BIO5.106.336.33MBIOMustang BioN/A0.740.74TLCTaiwan Liposome0.673.013.01OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABEOAbeona Therapeutics80.56%ALDXAldeyra Therapeutics59.71%KALAKALA BIO24.61%MBIOMustang Bio9.95%TLCTaiwan Liposome0.22%Insider OwnershipCompanyInsider OwnershipABEOAbeona Therapeutics5.30%ALDXAldeyra Therapeutics7.30%KALAKALA BIO13.40%MBIOMustang Bio2.10%TLCTaiwan LiposomeN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableABEOAbeona TherapeuticsN/A27.35 million25.91 millionOptionableALDXAldeyra Therapeutics1558.90 million54.60 millionOptionableKALAKALA BIO432.82 million2.44 millionNot OptionableMBIOMustang Bio8010.39 million10.17 millionNot OptionableTLCTaiwan Liposome2,02042.08 millionN/ANot OptionableABEO, TLC, ALDX, KALA, and MBIO HeadlinesSourceHeadlineAngela Deem accuses TLC of forcing her to 'keep her mouth shut' in unhinged rantmsn.com - April 23 at 11:14 PMHow to watch TLC’s ‘Little People, Big World’ new episodes free April 23masslive.com - April 23 at 6:13 PMWhy Kody Brown is the Most Disliked TLC Villain of All Timeyahoo.com - April 21 at 12:36 PM'I end up pooping myself on stage,' man cries after botched weight loss surgery in new TLC showmsn.com - April 19 at 10:23 AM‘7 Little Johnstons’ Season 14: How to watch episode 6 on TLC for freemsn.com - April 16 at 7:23 PMMonday: ‘Seeking Sister Wife’ Season 5, episode 7: How to watch TLC online for freecleveland.com - April 15 at 7:49 PMSee inside three-bed end terrace on sale for just £35k, but it needs serious TLCmsn.com - April 15 at 9:47 AMThe Disco Biscuits Nod To OutKast, TLC, Gucci Mane, & More In Atlanta [Video/Audio]liveforlivemusic.com - April 14 at 6:18 PMRico Wade, legendary Atlanta producer who worked with OutKast and co-wrote TLC's 'Waterfalls,' dies at 52msn.com - April 13 at 8:27 PMRico Wade, TLC ‘Waterfalls’ Cowriter and Southern Rap Trailblazer, Dies at 52thewrap.com - April 13 at 3:27 PMMorris continues new Brooks-TLC pleaobservertoday.com - April 12 at 8:34 AMTLC starts $27m upgradeaustralianageingagenda.com.au - April 11 at 8:17 PMTLC donates to Clatsop Animal Assistancedailyastorian.com - April 11 at 10:16 AMTLC Should Cancel ‘Sister Wives’ After Garrison Brown’s Suicidemsn.com - April 10 at 6:46 PMHow to watch TLC’s ‘Take My Tumor’ season 1, episode 2, stream for freepennlive.com - April 10 at 1:45 PMCrimestoppers seek tips on $500+ equipment theft from TLC Tree Service in Pananewschannel20.com - April 9 at 3:11 PM‘Seeking Sister Wife’ Season 5, episode 6: How to watch TLC online for freecleveland.com - April 8 at 7:40 PMHow to watch TLC’s ‘Seeking Sister Wife’ new episode free Monday, April 8masslive.com - April 8 at 7:40 PM'OutDaughtered' and 'Doubling Down With the Derricos' Finally Returning to TLC—See the Exclusive Teasersmsn.com - April 8 at 2:39 PMTLC is coming to the 2024 Wisconsin State Fair, with Jordin Sparks opening the concertmsn.com - April 8 at 2:39 PMFans Rejoice as ‘OutDaughtered’ and ‘Doubling Down With the Derricos’ Set to Premiere New Seasons on TLCmsn.com - April 8 at 2:39 PM2024 Wisconsin State Fair: TLC takes Main Stageyahoo.com - April 8 at 9:39 AM2024 Wisconsin State Fair: TLC takes Main Stage, Aug. 2fox6now.com - April 8 at 9:39 AMGoonya Fighter: First-Aid Boxes and some TLCkotaku.com - April 7 at 8:14 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAbeona TherapeuticsNASDAQ:ABEOAbeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Aldeyra TherapeuticsNASDAQ:ALDXAldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company's clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.KALA BIONASDAQ:KALAKALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Mustang BioNASDAQ:MBIOMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Taiwan LiposomeNASDAQ:TLCTaiwan Liposome Co., Ltd. engages in the research and development of lipid-based formulation drugs. Its products are used for pain management, eye disease treatment, and cancer treatment. The company was founded by Kee Lung Hong on November 10, 1997 and is headquartered in Taipei, Taiwan. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.